Trial Profile

A retrospective real world study assessing compared the effectiveness of Rd in combination with proteasome inhibitors, ixazomib (I), carfilzomib (K), and bortezomib (V), or monoclonal antibodies, elotuzumab (E) and daratumumab (D) with respect to treatment outcomes among RRMM patients in the United States (US) within subgroups defined by cytogenetic risk

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 23 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Elotuzumab (Primary) ; Ixazomib (Primary) ; Lenalidomide (Primary) ; Proteasome inhibitors (Primary)
Indications Multiple myeloma
Focus Therapeutic Use

23 Jan 2023 New trial record
13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com